Glycorex Transplantation
1.34 SEK
-4.29 %
Less than 1K followers
GTAB B
NGM Main Regulated
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Valuation
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Glycorex Transplantation
P/E
Median 2019-2025
EV/S
Median 2019-2022
EV/EBIT
Median 2019-2022
P/B
Median 2019-2025
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Share price (SEK) | 10.40 | 11.50 | 9.30 | 4.10 | 1.33 | 2.04 | 1.59 |
| Shares | 69.9 | 73.3 | 73.9 | 73.9 | 73.9 | 73.9 | 78.9 |
| Market cap | 726.5 | 843.2 | 686.8 | 302.8 | 97.9 | 150.7 | 125.4 |
| Enterprise value | 725.2 | 803.3 | 653.8 | 270.6 | - | - | - |
| EV/S | 20.1 | 29.8 | 23.2 | 7.5 | - | - | - |
| EV/EBITDA | 57.6 | 7,578.0 | neg. | 1,082.2 | - | - | - |
| EV/EBIT | 96.7 | neg. | neg. | neg. | - | - | - |
| P/E | 105.3 | neg. | neg. | neg. | neg. | neg. | neg. |
| P/B | 11.47 | 8.86 | 8.28 | 4.07 | 2.22 | 4.55 | 3.63 |
| P/S | 20.1 | 31.2 | 24.4 | 8.4 | 3.3 | 4.3 | 3.2 |
| Dividend yield | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % |
| Equity ratio | 73.8 % | 84.5 % | 81.5 % | 77.4 % | 66.9 % | 65.8 % | 68.0 % |
| Gearing ratio | 22.6 % | 9.8 % | 10.9 % | 1.8 % | 26.1 % | 21.1 % | 20.2 % |